ArticleJournal of gastrointestinal oncology2025
Molecular characterisation of Mozambican patients diagnosed with colorectal adenocarcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) represents a major healthcare problem worldwide, with significant impact in more unfavourable populations. Reports sustain an increased frequency of cases in these populations; however, the real scale remains to be fully disclosed. Data unveil that CRC in Africa manifests at younger age and in advanced stages of the disease that, in combination with scarce clinical strategies to manage patient treatment, leads to high rates of mortality. In this study, we aim to address the mutation landscape of Mozambican CRC tumours to improve the patient clinical management, focusing on Methods: A patient sample set of 30 CRC tumours from Mozambican patients was used to assess mutations in Results: Our results, opposing to previous reports published on African or African descent populations, reveal a predominance of mutations in KRAS and overexpression of p53 protein, with much lower mutation frequencies in the remaining genes. Conclusions: Identification of the mutational pattern of Mozambican CRC patients can help Mozambican clinicians better optimise treatment planning and therefore patient's outcome. Promising results obtained in our study, allied to scarcity of molecular data from Mozambican CRC patients, make imperative to enlarge our patient sample set to obtain more clinicopathological data and demographic/ancestry information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.